Akari Therapeutics appoints Abizer Gaslightwala as President and CEO
Boston and London, March 20, 2025 (Globe Newswire) -- Akari Therapeutics has named Abizer Gaslightwala as its new President and CEO, effective April 21, 2025, as the company advances its next-generation antibody-drug conjugates for cancer treatment. Gaslightwala, formerly Senior Vice President and Franchise Head for US Oncology at Jazz Pharmaceuticals, brings 25 years of leadership experience, having overseen a $1 billion oncology portfolio and held key roles at Amgen, Pfizer, and Johnson & Johnson. Outgoing CEO Samir Patel will remain on the board, supporting Akari’s continued strategic growth.
Read full article here.